应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00013 和黄医药
未开盘 05-14 16:08:20
34.450
-0.250
-0.72%
最高
35.900
最低
34.100
成交量
316.45万
今开
34.700
昨收
34.700
日振幅
5.19%
总市值
300.15亿
流通市值
300.15亿
总股本
8.71亿
成交额
1.11亿
换手率
0.36%
流通股本
8.71亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
和黄医药(US ADR)下跌2.13%,报21.315美元/股
金融界 · 05-14 22:29
和黄医药(US ADR)下跌2.13%,报21.315美元/股
【券商聚焦】国泰君安维持和黄医药(00013)“增持”评级 看好呋喹替尼海外市场进一步打开
金吾资讯 · 05-14 15:37
【券商聚焦】国泰君安维持和黄医药(00013)“增持”评级 看好呋喹替尼海外市场进一步打开
和黄医药(00013.HK)伙恒瑞医药启动联合疗法治疗胰腺导管腺癌临床试验
阿斯达克财经 · 05-14 09:17
和黄医药(00013.HK)伙恒瑞医药启动联合疗法治疗胰腺导管腺癌临床试验
和黄医药(00013)在中国启动HMPL-306治疗伴有IDH1及/或IDH2突变的复发/难治性急性髓系白血病患者的RAPHAEL注册性III期研究
智通财经 · 05-14 09:05
和黄医药(00013)在中国启动HMPL-306治疗伴有IDH1及/或IDH2突变的复发/难治性急性髓系白血病患者的RAPHAEL注册性III期研究
和黄医药(00013)与恒瑞医药达成合作并启动“索凡替尼”联合“卡瑞利珠单抗”用于治疗初治胰腺导管腺癌的II/III期研究
智通财经 · 05-14 08:59
和黄医药(00013)与恒瑞医药达成合作并启动“索凡替尼”联合“卡瑞利珠单抗”用于治疗初治胰腺导管腺癌的II/III期研究
和黄医药05月13日主力资金流出1886万元 连续3日减仓
自选股智能写手 · 05-13 16:16
和黄医药05月13日主力资金流出1886万元 连续3日减仓
和黄医药(US ADR)上涨5.09%,报21.88美元/股
金融界 · 05-10
和黄医药(US ADR)上涨5.09%,报21.88美元/股
和黄医药盘中异动 早盘股价大涨5.12%
自选股智能写手 · 05-10
和黄医药盘中异动 早盘股价大涨5.12%
和黄医药(00013)上涨5.01%,报32.5元/股
金融界 · 05-09
和黄医药(00013)上涨5.01%,报32.5元/股
和黄医药盘中异动 股价大涨5.01%
自选股智能写手 · 05-09
和黄医药盘中异动 股价大涨5.01%
和黄医药(00013.HK):言思雅获委任为独立非执行董事
格隆汇资讯 · 05-08
和黄医药(00013.HK):言思雅获委任为独立非执行董事
瑞银:维持和黄医药(00013)“买入”评级 目标价升至39港元
智通财经 · 05-08
瑞银:维持和黄医药(00013)“买入”评级 目标价升至39港元
《大行》瑞银升和黄医药(00013.HK)目标价至39元 首季销售势头良好
阿斯达克财经 · 05-08
《大行》瑞银升和黄医药(00013.HK)目标价至39元 首季销售势头良好
国君晨报0506|宏观、海外宏观、策略、食饮、化妆品、和黄医药
国泰君安证券研究 · 05-06
国君晨报0506|宏观、海外宏观、策略、食饮、化妆品、和黄医药
和黄医药(00013)呋喹替尼欧日获批在即,海外放量可期
国泰君安 · 04-30
和黄医药(00013)呋喹替尼欧日获批在即,海外放量可期
港股概念追踪 |ASCO研究标题发布 机构关注国产创新药产业机会(附概念股)
智通财经 · 04-30
港股概念追踪 |ASCO研究标题发布 机构关注国产创新药产业机会(附概念股)
和黄医药(US ADR)上涨4.9%,报19.05美元/股
金融界 · 04-29
和黄医药(US ADR)上涨4.9%,报19.05美元/股
和黄医药(00013)上涨5.11%,报31.9元/股
金融界 · 04-29
和黄医药(00013)上涨5.11%,报31.9元/股
和黄医药盘中异动 早盘大幅拉升5.10%
自选股智能写手 · 04-29
和黄医药盘中异动 早盘大幅拉升5.10%
和黄医药(00013.HK)合作伙伴武田创新药呋喹替尼获CHMP积极意见
阿斯达克财经 · 04-28
和黄医药(00013.HK)合作伙伴武田创新药呋喹替尼获CHMP积极意见
暂无数据
公司概况
公司名称:
和黄医药
所属市场:
SEHK
上市日期:
--
主营业务:
和黄医药(中国)有限公司(原名:和黄中国医药科技有限公司)是一家主要从事药品制造及销售的投资控股公司。连同其附属公司,该公司通过两个分部经营业务。肿瘤及免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法,包括涵盖药物发现、开发、生产及监管职能的研发活动,以及支持研发业务的行政活动,还包括通过研发活动开发的药物的销售、推广、生产及分销。其他业务分部从事其他商业化业务,包括其他处方药物及非处方药物以及消费保健品的销售、推广、生产及分销。
发行价格:
--
{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":34.45,"timestamp":1715674100024,"preClose":34.7,"halted":0,"volume":3164500,"delay":0,"floatShares":871256270,"shares":871256270,"eps":0.92633057,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.25,"latestTime":"05-14 16:08:20","open":34.7,"high":35.9,"low":34.1,"amount":110953650,"amplitude":0.051873,"askPrice":34.45,"askSize":500,"bidPrice":34.35,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":0.9263305869030419,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715823000000},"adr":0,"listingDate":1624982400000,"adjPreClose":34.7,"openAndCloseTimeList":[[1715650200000,1715659200000],[1715662800000,1715673600000]],"volumeRatio":0.5389471719284048,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013/tweets","defaultTab":"tweets","newsList":[{"id":"2435514713","title":"和黄医药(US ADR)下跌2.13%,报21.315美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435514713","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435514713?lang=zh_cn&edition=full","pubTime":"2024-05-14 22:29","pubTimestamp":1715696964,"startTime":"0","endTime":"0","summary":"5月14日,和黄医药(US ADR)(HCM)盘中下跌2.13%,截至22:29,报21.315美元/股,成交26.06万美元。财务数据显示,截至2023年12月31日,和黄医药(US ADR)收入总额8.38亿美元,同比增长96.52%;归母净利润1.01亿美元,同比增长127.93%。大事提醒:5月22日,和黄医药(US ADR)将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/14222940645655.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435565623","title":"【券商聚焦】国泰君安维持和黄医药(00013)“增持”评级 看好呋喹替尼海外市场进一步打开","url":"https://stock-news.laohu8.com/highlight/detail?id=2435565623","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2435565623?lang=zh_cn&edition=full","pubTime":"2024-05-14 15:37","pubTimestamp":1715672256,"startTime":"0","endTime":"0","summary":"随看欧日进一步获批,全球商业化放量有望加速,该行看好呋喹替尼海外市场进一步打开,维持“增持”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051415380887673bd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051415380887673bd9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435339045","title":"和黄医药(00013.HK)伙恒瑞医药启动联合疗法治疗胰腺导管腺癌临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2435339045","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2435339045?lang=zh_cn&edition=full","pubTime":"2024-05-14 09:17","pubTimestamp":1715649420,"startTime":"0","endTime":"0","summary":"和黄医药公布,启动一项中国II/III期临床试验,以评估和黄医药的候选药物索凡替尼、恒瑞医药的PD-1抗体卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨的联合疗法用于一线治疗转移性胰腺导管腺癌患者。胰腺导管腺癌是一种外分泌肿瘤,也是最常见的胰腺癌形式。首名受试者已于5月8日接受首次给药治疗。(港股报价延迟最少十五分钟。沽空资料截至 2024-05-13 16:25。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220520173825120_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220520173825120_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1349342/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2435386145","title":"和黄医药(00013)在中国启动HMPL-306治疗伴有IDH1及/或IDH2突变的复发/难治性急性髓系白血病患者的RAPHAEL注册性III期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2435386145","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435386145?lang=zh_cn&edition=full","pubTime":"2024-05-14 09:05","pubTimestamp":1715648720,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和黄医药 今日宣布在中国启动项HMPL-306治疗伴有异柠檬酸脱氢酶1或2突变的复发/难治性急性髓系白血病的注册性III期临床试验。HMPL-306是种新型的IDH1及IDH2酶双重抑制剂。IDH1及IDH2突变被认为是某些液恶性肿瘤、神经胶质瘤和实体瘤的驱动因素,尤其是对于急性髓系病患者来说。同时抑制IDH1和IDH2突变,有望克服这种获得性耐药,为癌症患者带来治疗获益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120868.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435253889","title":"和黄医药(00013)与恒瑞医药达成合作并启动“索凡替尼”联合“卡瑞利珠单抗”用于治疗初治胰腺导管腺癌的II/III期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2435253889","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435253889?lang=zh_cn&edition=full","pubTime":"2024-05-14 08:59","pubTimestamp":1715648392,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和黄医药 今日宣布启动一项中国II/III期临床试验,以评估和黄医药的候选药物索凡替尼、江苏恒瑞医药股份有限公司的PD-1抗体卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨的联合疗法用于一线治疗转移性胰腺导管腺癌患者。胰腺导管腺癌是一种外分泌肿瘤,也是最常见的胰腺癌形式。胰腺导管腺癌是一种高度侵袭性的癌症,占胰腺癌的90%以上。在中国,估计有11.9万人被诊断为患有胰腺癌,在2022年导致约10.6万人死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120866.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435454333","title":"和黄医药05月13日主力资金流出1886万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2435454333","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435454333?lang=zh_cn&edition=full","pubTime":"2024-05-13 16:16","pubTimestamp":1715588167,"startTime":"0","endTime":"0","summary":"05月13日, 和黄医药股价涨0.14%,报收34.70元,成交金额2.17亿元,换手率0.72%,振幅4.76%,量比1.14。和黄医药今日主力资金净流出1886万元,连续3日净流出,上一交易日主力净流出1133万元,今日环比增加66.46%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为27.78%,平均跌幅为2.20%。该股近5个交易日上涨9.09%,主力资金累计净流出3805万元;近20日主力资金累计净流出2050万元,其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051316165187613b49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051316165187613b49&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434852649","title":"和黄医药(US ADR)上涨5.09%,报21.88美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2434852649","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2434852649?lang=zh_cn&edition=full","pubTime":"2024-05-10 22:00","pubTimestamp":1715349649,"startTime":"0","endTime":"0","summary":"5月10日,和黄医药(US ADR)(HCM)盘中上涨5.09%,截至22:00,报21.88美元/股,成交98.15万美元。财务数据显示,截至2023年12月31日,和黄医药(US ADR)收入总额8.38亿美元,同比增长96.52%;归母净利润1.01亿美元,同比增长127.93%。大事提醒:5月22日,和黄医药(US ADR)将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/10220040605877.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434060071","title":"和黄医药盘中异动 早盘股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434060071","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434060071?lang=zh_cn&edition=full","pubTime":"2024-05-10 09:43","pubTimestamp":1715305398,"startTime":"0","endTime":"0","summary":"2024年05月10日早盘09时43分,和黄医药股票出现波动,股价急速拉升5.12%。截至发稿,该股报34.901港元/股,成交量145.598万股,换手率0.17%,振幅5.72%。和黄医药股票所在的药品行业中,整体涨幅为0.03%。公司透露,其合作伙伴武田药品的商业化团队已为呋喹替尼在欧盟的潜在上市做好充分准备,瑞银预期,一旦产品于欧盟及日本获批,和黄医药或可获取约2000万美元的里程碑费用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240510094319861ec3b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240510094319861ec3b9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434082949","title":"和黄医药(00013)上涨5.01%,报32.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2434082949","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2434082949?lang=zh_cn&edition=full","pubTime":"2024-05-09 09:39","pubTimestamp":1715218764,"startTime":"0","endTime":"0","summary":"5月9日,和黄医药(00013)盘中上涨5.01%,截至09:39,报32.5元/股,成交1114.96万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业,主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物,并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报,和黄医药营业总收入59.35亿元、净利润7.14亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/09093940576566.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434872140","title":"和黄医药盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434872140","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434872140?lang=zh_cn&edition=full","pubTime":"2024-05-09 09:39","pubTimestamp":1715218760,"startTime":"0","endTime":"0","summary":"2024年05月09日早盘09时39分,和黄医药股票出现异动,股价快速拉升5.01%。和黄医药股票所在的药品行业中,整体涨幅为0.04%。其相关个股中,和黄医药、东阳光长江药业、康龙化成涨幅较大,振幅较大的相关个股有君圣泰医药-B、东阳光长江药业、和黄医药,振幅分别为17.65%、5.19%、5.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050909392187e868e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050909392187e868e1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433748707","title":"和黄医药(00013.HK):言思雅获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2433748707","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2433748707?lang=zh_cn&edition=full","pubTime":"2024-05-08 17:26","pubTimestamp":1715160400,"startTime":"0","endTime":"0","summary":"格隆汇5月8日丨和黄医药(00013.HK)发布公告,言思雅获委任为公司独立非执行董事及技术委员会成员,自2024年5月13日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050817265287dfdd68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050817265287dfdd68&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433626857","title":"瑞银:维持和黄医药(00013)“买入”评级 目标价升至39港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433626857","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433626857?lang=zh_cn&edition=full","pubTime":"2024-05-08 10:37","pubTimestamp":1715135838,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,瑞银发布研究报告称,维持和黄医药“买入”评级,将治疗一线PDAC的索凡替尼纳入产品管线预测后,目标价从35.7港元升至39港元。公司透露,其合作伙伴武田药品的商业化团队已为呋喹替尼在欧盟的潜在上市做好充分准备,瑞银预期,一旦产品于欧盟及日本获批,和黄医药或可获取约2000万美元的里程碑费用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1118600.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433766081","title":"《大行》瑞银升和黄医药(00013.HK)目标价至39元 首季销售势头良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2433766081","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2433766081?lang=zh_cn&edition=full","pubTime":"2024-05-08 09:31","pubTimestamp":1715131860,"startTime":"0","endTime":"0","summary":"瑞银发表报告指,近日参与了和黄医药的投资者路演活动,一众投资者主要关注该公司首季销售表现,以及旗下研发的抗癌药物呋喹替尼审批进展,而管理层则对今年首季销售增长持正面看法,并维持全年肿瘤及免疫类产品收入介乎3亿至4亿美元的指引,并指出欧洲药品管理局人用医药产品委员会态度积极,令呋喹替尼在欧盟地区获批的可见度提高,预计该产品可于今年6月及10月左右分别在欧盟及日本获批。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220520173825120_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220520173825120_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1348016/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2433651834","title":"国君晨报0506|宏观、海外宏观、策略、食饮、化妆品、和黄医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2433651834","media":"国泰君安证券研究","top":-1,"share":"https://www.laohu8.com/m/news/2433651834?lang=zh_cn&edition=full","pubTime":"2024-05-06 06:59","pubTimestamp":1714949940,"startTime":"0","endTime":"0","summary":"本次会议对防范化解重点领域风险提出了更高要求。与此同时,昨日恒生指数也出现了大涨,并站上18,000点的关口。来自经济、政策、股市不确定性的降低,有望推动投资者对风险接纳程度的改善、预期的修复与仓位的回补,投资机会在年中,A股有望震荡上升。政策避免“前紧后松”打消疑虑,三中全会引领改革预期升温。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650479570&idx=2&sn=5d2510471d202c4b24a165c64cd9aa98&chksm=89f8e8167a5fb902eaec0ef9e130dd6716f174526b3f1a26a9666bf6851743492f00f94c66fe&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2431364650","title":"和黄医药(00013)呋喹替尼欧日获批在即,海外放量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2431364650","media":"国泰君安","top":-1,"share":"https://www.laohu8.com/m/news/2431364650?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:14","pubTimestamp":1714461294,"startTime":"0","endTime":"0","summary":"摘要:事件:呋喹替尼继2023.11月美国获批后,近期欧洲药品管理局人用药品委员会给予积极意见支持呋喹替尼用于治疗经治转移性结直肠癌,有望近期获批上市。2023.9月呋喹替尼向日本递交了NDA,有望24年内获批上市。我们看好呋喹替尼海外市场进一步打开,维持“增持”评级。此外,公司有望于24年底披露呋喹替尼治疗肾细胞癌II/III期顶线结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043015321987c2b0b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043015321987c2b0b4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431488359","title":"港股概念追踪 |ASCO研究标题发布 机构关注国产创新药产业机会(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2431488359","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431488359?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:00","pubTimestamp":1714456822,"startTime":"0","endTime":"0","summary":"2024年美国临床肿瘤学会年会的研究标题于4月25日公布,纳入约5900余摘要。工银瑞信基金认为,考虑到将在二季度举办的美国临床肿瘤学会年会将有大量ADC数据读出,届时将对创新药形成催化,叠加行业本身的政策利好,长期维度来看创新药板块仍值得关注。该行看好公司作为全球实体瘤CAR-T龙头企业,其CT053、CT041等管线陆续商业化带来成长性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116125.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431671864","title":"和黄医药(US ADR)上涨4.9%,报19.05美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431671864","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431671864?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:14","pubTimestamp":1714400057,"startTime":"0","endTime":"0","summary":"4月29日,和黄医药(US ADR)(HCM)盘中上涨4.9%,截至22:14,报19.05美元/股,成交166.19万美元。财务数据显示,截至2023年12月31日,和黄医药(US ADR)收入总额8.38亿美元,同比增长96.52%;归母净利润1.01亿美元,同比增长127.93%。大事提醒:5月22日,和黄医药(US ADR)将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/29221440477714.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431040747","title":"和黄医药(00013)上涨5.11%,报31.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431040747","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431040747?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:19","pubTimestamp":1714357155,"startTime":"0","endTime":"0","summary":"4月29日,和黄医药(00013)盘中上涨5.11%,截至10:19,报31.9元/股,成交3450.93万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业,主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物,并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2023年年报,和黄医药营业总收入59.35亿元、净利润7.14亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29101940459601.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431020040","title":"和黄医药盘中异动 早盘大幅拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431020040","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431020040?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:19","pubTimestamp":1714357151,"startTime":"0","endTime":"0","summary":"2024年04月29日早盘10时19分,和黄医药股票出现异动,股价快速拉升5.10%。截至发稿,该股报31.900港元/股,成交量111.25万股,换手率0.13%,振幅6.26%。和黄医药股票所在的药品行业中,整体涨幅为0.29%。其相关个股中,泰凌医药、长江生命科技、联康生物科技集团涨幅较大,振幅较大的相关个股有三爱健康集团、泰凌医药、和黄医药,振幅分别为19.23%、11.54%、5.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042910191187e84888&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042910191187e84888&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430065498","title":"和黄医药(00013.HK)合作伙伴武田创新药呋喹替尼获CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2430065498","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430065498?lang=zh_cn&edition=full","pubTime":"2024-04-28 22:54","pubTimestamp":1714316040,"startTime":"0","endTime":"0","summary":"和黄医药公布,合作伙伴武田取得欧洲药品管理局“EMA”人用药品委员会“CHMP”建议批准呋喹替尼用于治疗经治的成人转移性结直肠癌患者。欧盟委员会 在决定呋喹替尼用于治疗转移性结直肠癌在整个欧盟、挪威、列支敦士登和冰岛的上市许可时,将会把CHMP的积极意见纳入考量。倘获批,呋喹替尼将成为欧盟批准用于经治转移性结直肠癌的第一个也是唯一一个所有三种血管内皮生长因子受体“VEGFR”的选择性抑制剂。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345625/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.1131},{"period":"1month","weight":0.19},{"period":"3month","weight":0.6643},{"period":"6month","weight":0.2173},{"period":"1year","weight":0.5731},{"period":"ytd","weight":0.2003}],"compareEarnings":[{"period":"1week","weight":0.0322},{"period":"1month","weight":0.1407},{"period":"3month","weight":0.2012},{"period":"6month","weight":0.0696},{"period":"1year","weight":-0.0449},{"period":"ytd","weight":0.1189}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药(中国)有限公司(原名:和黄中国医药科技有限公司)是一家主要从事药品制造及销售的投资控股公司。连同其附属公司,该公司通过两个分部经营业务。肿瘤及免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法,包括涵盖药物发现、开发、生产及监管职能的研发活动,以及支持研发业务的行政活动,还包括通过研发活动开发的药物的销售、推广、生产及分销。其他业务分部从事其他商业化业务,包括其他处方药物及非处方药物以及消费保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.130873},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058734},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.131658},{"month":4,"riseRate":0.666667,"avgChangeRate":0.04977},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.139406},{"month":6,"riseRate":0.5,"avgChangeRate":0.061545},{"month":7,"riseRate":1,"avgChangeRate":0.147985},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046428},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.081182},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.003665},{"month":11,"riseRate":0.666667,"avgChangeRate":0.265429},{"month":12,"riseRate":0.666667,"avgChangeRate":0.027237}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}